Evogene
AI-guided small-molecule discovery for medicines and crop protection.
Something off on this page? Send us feedback.
Profile
Develops AI-designed small molecules for pharmaceutical and crop-protection programs, earning collaboration payments, potential milestones and royalties, while also selling castor seed varieties and support. The business is concentrated around ChemPass AI after divesting or reducing other computational-biology activities.
Uses ChemPass AI to design and optimize small molecules for drug discovery and crop protection. Its computational unit combines virtual screening, analogue search and generative design with laboratory and validation capabilities across curated chemical spaces. Pharmaceutical collaborations pair molecular design with partners' experimental, development and commercialization work.
AgPlenus applies the agricultural platform to novel herbicides and fungicides, while Casterra retains high-yield castor seed varieties, agronomic support and Brazil-focused operations. Revenue can arise from partner payments, research funding, milestones and royalties, alongside seed sales. Candidate progression depends on experimental validation, development partners, regulatory approvals, intellectual-property protection and access to external capital.
Company facts
Categories
Key statistics
Year to date −52.1% · Average volume (30d) 471.3K
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Target |
|---|---|---|---|
| May 26, 2026 | Industrial Alliance Securities | Target | $2.15 |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 18, 2026Q2 FY26 | −$0.27 | −$0.13 | +51.9% | $325.0K | $347.0K | +6.8% | +4.04% |
| May 20, 2026Q1 FY26 | −$0.27 | −$0.60 | −122.2% | $350.0K | $334.0K | −4.6% | −3.68% |
| Mar 5, 2026Q4 FY25 | −$0.26 | −$0.61 | −134.6% | $275.0K | $314.0K | +14.2% | −2.38% |
| Nov 20, 2025Q3 FY25 | −$0.26 | −$0.31 | −19.2% | $275.0K | $312.0K | +13.5% | +4.63% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $2.4M | $884.0K | $312.0K | $314.0K | $334.0K | $347.0K | |
| Gross profit | $830.0K | $748.0K | $155.0K | −$2.0M | $204.0K | −$8.0K | |
| Operating income | −$4.1M | −$3.1M | −$2.7M | −$5.2M | −$3.2M | −$2.4M | |
| Net income | −$2.6M | −$4.5M | $3.9M | −$5.3M | −$5.9M | −$1.8M | |
| Diluted EPS | −$0.38 | −$0.62 | $0.44 | −$0.61 | −$0.60 | −$0.14 | |
| Gross margin | 34.0% | 84.6% | 49.7% | -627.4% | 61.1% | -2.3% | |
| Operating margin | -168.8% | -347.4% | -873.1% | -1,659.9% | -943.1% | -703.5% |
Fiscal years (4-quarter sums)FY21 $930.0K · FY22 $1.7M · FY23 $5.6M · FY24 $8.1M · FY25 $4.0M
Balance sheet, Jun 30, 2026Cash & short-term investments $9.4M · Total debt $2.1M · Total assets $13.4M · Shareholders' equity −$3.3M
Dividends
No dividends on record.
Ownership
Shares outstanding 8.62M · Float —
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| L.I.A. Pure Capital Ltd. | 3.06M | 19.35% | 13D | Aug 28, 2026 |
| Leon Recanati · director | 1.34M | 15.60% | Form 4 | Aug 13, 2026 |
| Armistice Capital, LLC | 1.10M | 9.99% | 13G | May 15, 2026 |
| Gabi Tarcic · officer: Chief Development Officer | 1.1K | 0.01% | Form 4 | Aug 26, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Jun 4, 2026 | Gabi Tarcic | officer: Chief Development Officer | +1,129 | $0.6000 |
| Aug 11, 2026 | Leon Recanati | director | +460,000 | $0.6350 |
| Aug 4, 2026 | Leon Recanati | director | +800,000 | $0.5000 |
Peers
- Schrödinger
Physics-plus-AI design platform for small-molecule discovery.
- Recursion Pharmaceuticals
AI-native chemistry and biology platform for partnered drug programs.
- FMC
Global crop-protection innovator in herbicide and fungicide discovery.
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Evogene | $0.5490 | +1.48% | $4.7M | — | — | 3.5 | −60.8% |
| Schrödinger | $19.67 | −0.15% | $1.47B | — | — | 5.7 | +7.5% |
| Recursion Pharmaceuticals | $3.35 | +0.60% | $1.75B | — | — | 31.9 | −61.8% |
| FMC | $11.32 | 0.00% | $1.42B | — | 8.0 | 0.4 | −17.5% |
| Median | — | 8.0 | 5.7 | −17.5% |